Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis Steps In With $66 Billion White Knight Offer For Allergan, Ending Valeant Acquisition Plans

This article was originally published in The Gray Sheet

Executive Summary

The generics giant came through with the transformational deal it promised shareholders, bidding $66 billion for Allergan, and effectively wiping out Valeant’s hopes that it could take over the drug and device maker.


Related Content

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts